Hossein Tabriziani, Senior Medical Director, Organ Health and Transplant at Natera and Chief Medical Officer at HossMed, shared a post on LinkedIn about a recent paper she co-authored with colleagues published in the American Journal of Transplantation:
“I am pleased to share that our recent study, PEDAL (The Prospera Enhancement by Detecting dd-cfDNA Levels), has been published in the American Journal of Transplantation (AJT).
In this prospective, multicenter study of kidney transplant recipients with biopsy-proven acute rejection, we evaluated whether post-rejection monitoring of dd-cfDNA could stratify patients by prognosis. By tracking dd-cfDNA trends over the eight weeks following rejection diagnosis, we identified four distinct patterns, two associated with favorable outcomes and two with unfavorable outcomes.
These trends were strongly associated with 12-month clinical outcomes, including graft survival, recurrent rejection, donor-specific antibody development, and recovery of renal function, demonstrating the prognostic value of dd-cfDNA in post-rejection management.
I would like to sincerely thank all the principal investigators who contributed to the PEDAL study and made this work possible. Their dedication, collaboration, and expertise were essential, and without their efforts this study could not have been accomplished.”
Title: Associations between donor-derived cell-free DNA dynamics and clinical outcomes after kidney allograft rejection: A prospective, multicenter study
Authors: Suphamai Bunnapradist, Nicolae Leca, Ziad S. Zaky, Robert J. Stratta, Hasan A. Khamash, Fuad Shihab, Obi Ekwenna, Martin Aldana-Campos, Joseph Kahwaji, Luigi Biancone, Thin Thin Maw, D. Giovanni Biagini, Navchetan Kaur, Adam Prewett, Geethanjali Gude, Paul Van Hummelen, Michelle S. Bloom, Zachary Demko, Matthew Rabinowitz, Steven L. Chapman, Phil Gauthier, Sangeeta Bhorade, Hossein Tabriziani, Yasir Qazi
Read the Full Article in the American Journal of Transplantation.
More posts on OncoDaily.